Search by Drug Name or NDC

    NDC 47783-0644-01 TAKHZYRO 300 mg/2mL Details

    TAKHZYRO 300 mg/2mL

    TAKHZYRO is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is LANADELUMAB.

    Product Information

    NDC 47783-0644
    Product ID 47783-644_7b67bee7-cd75-431e-949e-39399e849426
    Associated GPIs 85842040202020
    GCN Sequence Number 078791
    GCN Sequence Number Description lanadelumab-flyo VIAL 300 MG/2ML SUBCUT
    HIC3 A7N
    HIC3 Description PLASMA KALLIKREIN INHIBITORS
    GCN 45184
    HICL Sequence Number 045177
    HICL Sequence Number Description LANADELUMAB-FLYO
    Brand/Generic Brand
    Proprietary Name TAKHZYRO
    Proprietary Name Suffix n/a
    Non-Proprietary Name lanadelumab-flyo
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 300
    Active Ingredient Units mg/2mL
    Substance Name LANADELUMAB
    Labeler Name Takeda Pharmaceuticals America, Inc.
    Pharmaceutical Class Kallikrein Inhibitors [MoA], Plasma Kallikrein Inhibitor [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761090
    Listing Certified Through 2024-12-31

    Package

    NDC 47783-0644-01 (47783064401)

    NDC Package Code 47783-644-01
    Billing NDC 47783064401
    Package 1 VIAL, GLASS in 1 CARTON (47783-644-01) / 5 mL in 1 VIAL, GLASS
    Marketing Start Date 2018-08-24
    NDC Exclude Flag N
    Pricing Information N/A